ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,363,258 | -4.9% | 1,073,093 | +9.3% | 0.01% | -14.3% |
| Q2 2023 | $23,505,775 | +28.9% | 981,452 | +1.3% | 0.01% | +16.7% |
| Q1 2023 | $18,242,113 | +17.9% | 969,294 | -0.3% | 0.01% | +20.0% |
| Q4 2022 | $15,470,324 | -0.7% | 971,754 | +2.0% | 0.01% | -16.7% |
| Q3 2022 | $15,586,000 | +20.6% | 952,674 | +3.9% | 0.01% | +50.0% |
| Q2 2022 | $12,923,000 | -43.0% | 917,161 | -2.1% | 0.00% | -42.9% |
| Q1 2022 | $22,689,000 | +10.1% | 936,774 | +6.1% | 0.01% | +16.7% |
| Q4 2021 | $20,610,000 | +51.1% | 883,001 | +7.5% | 0.01% | +50.0% |
| Q3 2021 | $13,639,000 | -49.6% | 821,102 | -26.0% | 0.00% | -55.6% |
| Q2 2021 | $27,058,000 | +23.9% | 1,109,369 | +31.0% | 0.01% | +12.5% |
| Q1 2021 | $21,842,000 | -52.3% | 846,563 | -1.3% | 0.01% | -55.6% |
| Q4 2020 | $45,835,000 | +24.1% | 857,370 | -4.3% | 0.02% | +5.9% |
| Q3 2020 | $36,942,000 | +3.7% | 895,547 | +21.8% | 0.02% | 0.0% |
| Q2 2020 | $35,629,000 | +0.0% | 735,065 | -12.8% | 0.02% | -19.0% |
| Q1 2020 | $35,615,000 | +13.9% | 842,958 | +15.3% | 0.02% | +23.5% |
| Q4 2019 | $31,265,000 | +36.7% | 730,823 | +15.0% | 0.02% | +21.4% |
| Q3 2019 | $22,878,000 | +17.1% | 635,672 | -13.0% | 0.01% | +16.7% |
| Q2 2019 | $19,540,000 | +3.7% | 730,992 | +4.1% | 0.01% | 0.0% |
| Q1 2019 | $18,848,000 | +97.3% | 701,961 | +18.8% | 0.01% | +71.4% |
| Q4 2018 | $9,554,000 | -19.7% | 590,806 | +3.1% | 0.01% | -12.5% |
| Q3 2018 | $11,896,000 | +10.6% | 572,978 | -18.6% | 0.01% | 0.0% |
| Q2 2018 | $10,753,000 | +7.2% | 704,162 | +57.8% | 0.01% | 0.0% |
| Q1 2018 | $10,029,000 | -26.1% | 446,291 | -1.0% | 0.01% | -27.3% |
| Q4 2017 | $13,571,000 | -14.8% | 450,709 | +6.7% | 0.01% | -21.4% |
| Q3 2017 | $15,920,000 | +46.7% | 422,605 | +8.6% | 0.01% | +40.0% |
| Q2 2017 | $10,853,000 | -13.5% | 389,127 | +6.6% | 0.01% | -23.1% |
| Q1 2017 | $12,548,000 | +41.4% | 364,962 | +18.6% | 0.01% | +30.0% |
| Q4 2016 | $8,874,000 | -9.4% | 307,683 | -0.0% | 0.01% | -16.7% |
| Q3 2016 | $9,790,000 | +51.9% | 307,759 | +55.0% | 0.01% | +50.0% |
| Q2 2016 | $6,445,000 | -26.0% | 198,523 | -36.2% | 0.01% | -27.3% |
| Q1 2016 | $8,707,000 | -15.9% | 311,403 | +7.2% | 0.01% | -21.4% |
| Q4 2015 | $10,357,000 | +13.6% | 290,504 | +5.4% | 0.01% | +7.7% |
| Q3 2015 | $9,117,000 | -17.9% | 275,677 | +3.9% | 0.01% | -13.3% |
| Q2 2015 | $11,110,000 | +32.6% | 265,262 | +3.2% | 0.02% | +25.0% |
| Q1 2015 | $8,381,000 | +19.2% | 257,148 | +16.1% | 0.01% | +9.1% |
| Q4 2014 | $7,030,000 | +33.1% | 221,394 | +3.8% | 0.01% | +22.2% |
| Q3 2014 | $5,280,000 | +7.9% | 213,225 | -1.6% | 0.01% | +12.5% |
| Q2 2014 | $4,895,000 | -2.5% | 216,662 | +5.1% | 0.01% | -11.1% |
| Q1 2014 | $5,018,000 | +8.0% | 206,238 | +10.9% | 0.01% | 0.0% |
| Q4 2013 | $4,647,000 | -7.1% | 185,924 | +4.4% | 0.01% | -10.0% |
| Q3 2013 | $5,004,000 | +74.8% | 178,134 | +13.0% | 0.01% | +66.7% |
| Q2 2013 | $2,863,000 | – | 157,706 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |